![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
September 6, 2024
September 5, 2024
Posts
;
Immune cell structures in tumors can boost immunotherapy & survival, but testing is labor-intensive & not yet common. At #AACR25, Ahmad Tarhini & Xuefeng Wang (@EAonc @MoffittNews) will present AI-driven methods to speed up testing for melanoma patients.
Press Release: Estimating complex immune cell structures by AI tools for survival prediction in...
Unique immune cell structures in tumors can boost immunotherapy effects and enhance survival, but testing is labor-int...
bit.ly
In #ClinicalTrial EA2222/PUMP, investigators are testing #PumpChemo in addition to SOC chemo versus SOC chemo alone for patients with unresectable #ColorectalCancer liver metastases. For more: https://bit.ly/ea2222-pump cc : @michael_lidsky
Do you have #KidneyCancer (#RenalCellCarcinoma) that has spread to 2-5 other locations in your body? If so, you may be able to participate in this study of a potential new treatment. Learn more: https://bit.ly/ea8211-study #kcsm
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
40
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
